Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Boehringer Ingelheim

Status: Terminated

Conditions: Venous Thromboembolism; Arthroplasty, Replacement

Treatments: Drug: dabigatran

Study type: Observational

Funder types: Industry

Identifiers

NCT01153698

1160.118

Details and patient eligibility

About

an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee replacement (TKR) and total hip replacement (THR)

Enrollment: 167 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

patients age 18 years or above undergoing elective total hip or knee replacement surgery

Exclusion criteria

according to the label recommendation for Pradaxa 220 mg QD

Trial design

167 participants in 1 patient group

patients after hip or knee replacement

Treatment:

Drug: dabigatran